Stoke Therapeutics, INC Form 4 insider transactions

Stoke Therapeutics' CEO and Director, Ian F. Smith, received significant equity awards, including stock options and restricted stock units, aligning his interests with long-term company performance.

Stoke Therapeutics' Chief Financial Officer, Thomas Leggett, was granted 60,000 stock options and 40,000 restricted stock units.

Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, was granted 72,000 stock options and 48,000 restricted stock units, aligning executive interests with long-term company performance.

Jonathan Allan, General Counsel of Stoke Therapeutics, reported the acquisition of 53,000 employee stock options and 35,000 restricted stock units.

Stoke Therapeutics Director Arthur A. Levin acquired 1,211 shares of common stock through the vesting of Restricted Stock Units.

Stoke Therapeutics General Counsel Jonathan Allan sold 3,978 shares of common stock on December 8, 2025, under a pre-arranged trading plan.

Stoke Therapeutics Director Edward M. Kaye, MD, sold 13,430 shares of common stock for approximately $433,540 through a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported the acquisition of 10,000 common shares from vested performance stock units and subsequent sales totaling 5,358 shares, primarily for tax obligations and a 10b5-1 plan.

Stoke Therapeutics Director Edward M. Kaye, MD, reported the acquisition of common stock from vested performance units and subsequent sales, primarily for tax obligations and a 10b5-1 plan.

Stoke Therapeutics' General Counsel, Jonathan Allan, reported the exercise of performance stock units and subsequent sales of common stock, including tax-related dispositions and sales under a 10b5-1 plan.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported the vesting of restricted stock units and subsequent sales of common stock to cover tax obligations.

Stoke Therapeutics Director Edward M. Kaye MD reported the sale of common stock to cover tax withholding liabilities following the vesting of restricted stock units.

Stoke Therapeutics' General Counsel, Jonathan Allan, reported the vesting of restricted stock units and subsequent sales of common stock to cover tax withholding liabilities.

Stoke Therapeutics Director Adrian R. Krainer sold 40,472 shares of common stock for approximately $29.72 per share under a pre-arranged trading plan.

Stoke Therapeutics Director Adrian R. Krainer sold 40,472 shares of common stock for approximately $1.09 million under a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 5,931 shares of common stock on November 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics CEO Ian F. Smith was granted 950,000 equity awards, including stock options and restricted stock units, aligning his interests with long-term shareholder value.

Edward M. Kaye, a director at Stoke Therapeutics, exercised stock options and subsequently sold 25,000 shares of common stock under a Rule 10b5-1 plan.

Stoke Therapeutics Director Edward M. Kaye, MD, sold 42,461 shares of common stock for approximately $1.06 million under a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics' General Counsel, Jonathan Allan, executed a pre-planned sale of 10,000 common shares after exercising stock options.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 5,343 shares of common stock for a weighted average price of $23.6414 per share.

Arthur A. Levin, a Director at Stoke Therapeutics, acquired 1,211 shares of common stock through the vesting and conversion of Restricted Stock Units.

Stoke Therapeutics Director Edward M. Kaye canceled 178,500 stock options and 144,000 Restricted Stock Units by mutual agreement with the company.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported a future sale of 5,501 shares of common stock for approximately $19.87 per share, executed under a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics Director Edward M. Kaye MD sold a total of 61,885 shares of common stock in late August and early September 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics' General Counsel, Jonathan Allan, executed planned sales of common stock following option exercises.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 2,805 shares of common stock to cover tax withholding liabilities related to restricted stock unit vesting.

Stoke Therapeutics Director Edward M. Kaye, MD, sold 12,126 shares of common stock to cover tax withholding liabilities related to restricted stock unit vesting.

Stoke Therapeutics' General Counsel, Jonathan Allan, sold 1,683 shares of common stock to cover tax withholding liabilities.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, increased his direct beneficial ownership of common stock by 10,000 shares and received a grant of 20,000 performance stock units.